Ventilator-associated pneumonia in the ICU

Ventilator-associated pneumonia (VAP) is defined as pneumonia that occurs 48–72 hours or thereafter following endotracheal intubation, characterized by the presence of a new or progressive infiltrate, signs of systemic infection (fever, altered white blood cell count), changes in sputum characteristics, and detection of a causative agent [1]. VAP contributes to approximately half of all cases of hospital-acquired pneumonia [1, 2]. VAP is estimated to occur in 9–27 % of all mechanically ventilated patients, with the highest risk being early in the course of hospitalization [1, 3]. It is the second most common nosocomial infection in the intensive care unit (ICU) and the most common in mechanically ventilated patients [4, 5]. VAP rates range from 1.2 to 8.5 per 1,000 ventilator days and are reliant on the definition used for diagnosis [6]. Risk for VAP is greatest during the first 5 days of mechanical ventilation (3 %) with the mean duration between intubation and development of VAP being 3.3 days [1, 7]. This risk declines to 2 %/day between days 5 to 10 of ventilation, and 1 %/day thereafter [1, 8]. Earlier studies placed the attributable mortality for VAP at between 33–50 %, but this rate is variable and relies heavily on the underlying medical illness [1]. Over the years, the attributable risk of death has decreased and is more recently estimated at 9–13 % [9, 10], largely because of implementation of preventive strategies. Approximately 50 % of all antibiotics administered in ICUs are for treatment of VAP [2, 4]. Early onset VAP is defined as pneumonia that occurs within 4 days and this is usually attributed to antibiotic sensitive pathogens whereas late onset VAP is more likely caused by multidrug resistant (MDR) bacteria and emerges after 4 days of intubation [1, 4]. Thus, VAP poses grave implications in endotracheally intubated adult patients in ICUs worldwide and leads to increased adverse outcomes and healthcare costs. Independent risk factors for development of VAP are male sex, admission for trauma and intermediate underlying disease severity, with odds ratios (OR) of 1.58, 1.75 and 1.47–1.70, respectively [7].

[1]  R. Ferrer,et al.  Efficacy of single-dose antibiotic against early-onset pneumonia in comatose patients who are ventilated. , 2013, Chest.

[2]  R. Pinciroli,et al.  Ventilator Associated Pneumonia: Evolving Definitions and Preventive Strategies , 2013, Respiratory Care.

[3]  谷口博之,et al.  急性肺損傷のstate of the art 人工呼吸器関連肺炎(ventilator associated pneumonia:VAP)の診断と治療 , 2002 .

[4]  M. Rovers,et al.  Estimating the attributable mortality of ventilator-associated pneumonia from randomized prevention studies* , 2011, Critical care medicine.

[5]  N. Behrendt,et al.  Evaluation of pneumonia diagnosis in intensive care patients. , 1999, Scandinavian journal of infectious diseases.

[6]  S. Harbarth,et al.  Year in review 2011: Critical Care - infection , 2012, Critical Care.

[7]  Phil Grgurich,et al.  Diagnosis of ventilator-associated pneumonia: controversies and working toward a gold standard , 2013, Current opinion in infectious diseases.

[8]  T. S. Wilkinson,et al.  Combined dysfunctions of immune cells predict nosocomial infection in critically ill patients. , 2013, British journal of anaesthesia.

[9]  Hong‐Lin Chen,et al.  Diagnostic Accuracy of Clinical Pulmonary Infection Score for Ventilator-Associated Pneumonia: A Meta-analysis , 2011, Respiratory Care.

[10]  M. Klompas,et al.  Toward improved surveillance: the impact of ventilator-associated complications on length of stay and antibiotic use in patients in intensive care units. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Rolf H H Groenwold,et al.  Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. , 2013, The Lancet. Infectious diseases.

[12]  Michel Wolff,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.

[13]  M. Niederman,et al.  Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors , 2013, Intensive Care Medicine.

[14]  Jordi Rello,et al.  Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. , 2002, Chest.

[15]  T. S. Wilkinson,et al.  C5a-mediated neutrophil dysfunction is RhoA-dependent and predicts infection in critically ill patients. , 2011, Blood.

[16]  R. Weinstein,et al.  Acinetobacter infection. , 2008, The New England journal of medicine.

[17]  P. J. Z. Teixeira,et al.  Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. , 2014, The Cochrane database of systematic reviews.

[18]  Kelly D Peterson,et al.  National Healthcare Safety Network (NHSN) Report, data summary for 2010, device-associated module. , 2011, American journal of infection control.

[19]  D. Annane,et al.  Early-Onset Ventilator-Associated Pneumonia in Adults Randomized Clinical Trial: Comparison of 8 versus 15 Days of Antibiotic Treatment , 2012, PloS one.

[20]  J. Hunter Ventilator associated pneumonia , 2012, BMJ : British Medical Journal.

[21]  T. Wiemken,et al.  Emergence of methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of late-onset nosocomial pneumonia in intensive care patients in the USA. , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[22]  D. Auerbach,et al.  The nursing workforce in an era of health care reform. , 2013, The New England journal of medicine.

[23]  T. S. Wilkinson,et al.  C 5 a-mediated neutrophil dysfunction is RhoA-dependent and predicts infection in critically ill patients , 2011 .

[24]  Mauricio Valencia,et al.  Ventilator-associated pneumonia , 2009, Current opinion in critical care.

[25]  M. Niederman,et al.  Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. , 1997, Chest.

[26]  Marin H Kollef,et al.  Recognition and prevention of nosocomial pneumonia in the intensive care unit and infection control in mechanical ventilation , 2010, Critical care medicine.

[27]  R. Auckenthaler,et al.  Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. , 1991, The American review of respiratory disease.

[28]  D. Mozingo A randomized trial of diagnostic techniques for ventilator-associated pneumonia. , 2006, The New England journal of medicine.

[29]  R. Wiener,et al.  Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. , 2011, Chest.

[30]  M. Kollef,et al.  Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. , 2013, Chest.

[31]  S. Ewig,et al.  Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies , 1999, Thorax.

[32]  D. Heyland,et al.  Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: A systematic review and meta-analysis* , 2011, Critical care medicine.

[33]  J. Carlet,et al.  Defining, treating and preventing hospital acquired pneumonia: European perspective , 2008, Intensive Care Medicine.

[34]  Jean-Yves Fagon,et al.  Ventilator-associated pneumonia. , 2002, American journal of respiratory and critical care medicine.

[35]  T. Similowski,et al.  Invasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated Pneumonia , 2000, Annals of Internal Medicine.

[36]  M. Klompas Complications of mechanical ventilation--the CDC's new surveillance paradigm. , 2013, The New England journal of medicine.

[37]  A. L. Da Costa Darini,et al.  Relationship between nasal colonization and ventilator-associated pneumonia and the role of the environment in transmission of Staphylococcus aureus in intensive care units. , 2013, American journal of infection control.

[38]  Michelle R Farber,et al.  Implementing a ventilator bundle in a community hospital. , 2007, Joint Commission journal on quality and patient safety.

[39]  V L Yu,et al.  Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. , 2000, American journal of respiratory and critical care medicine.

[40]  R. Masterton Antibiotic de-escalation. , 2011, Critical care clinics.

[41]  Gordon Guyatt,et al.  Incidence of and Risk Factors for Ventilator-Associated Pneumonia in Critically Ill Patients , 1998, Annals of Internal Medicine.

[42]  J. Barker A Randomized Trial of Diagnostic Techniques for Ventilator-Associated Pneumonia , 2008 .

[43]  T. Walsh,et al.  Reducing ventilator-associated pneumonia in intensive care: Impact of implementing a care bundle* , 2011, Critical care medicine.

[44]  J. Vincent,et al.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. , 1995, JAMA.

[45]  M. Kollef,et al.  Implementing quality improvements in the intensive care unit: Ventilator bundle as an example , 2009, Critical care medicine.

[46]  M. Klompas Does this patient have ventilator-associated pneumonia? , 2007, JAMA.

[47]  Saxon Ridley Critical care. , 2003, Anaesthesia.

[48]  古谷 良輔,et al.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.

[49]  G. D. Thomas,et al.  Nosocomial respiratory infections with gram-negative bacilli. The significance of colonization of the respiratory tract. , 1972, Annals of internal medicine.

[50]  D. Cook,et al.  Correlates of clinical failure in ventilator-associated pneumonia: insights from a large, randomized trial. , 2008, Journal of critical care.

[51]  P. Lipsett,et al.  Can the clinical pulmonary infection score impact ICU antibiotic days? , 2006, Surgical infections.

[52]  A. Shorr,et al.  Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  M. Kollef,et al.  A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria* , 2012, Critical care medicine.

[54]  R. Jaeschke,et al.  Small bowel feeding and risk of pneumonia in adult critically ill patients: a systematic review and meta-analysis of randomized trials , 2013, Critical Care.